secwatch.observer — SEC 8-K summary
======================================

Issuer:     Harmony Biosciences Holdings, Inc. (HRMY)
CIK:        0001802665
Form:       8-K
Filed at:   2025-08-05T23:59:59+00:00
Accession:  0001558370-25-010182
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Harmony Biosciences Q2 revenue $200.5M (+16% YoY); EPS $0.68; reaffirms FY guidance $820-860M
--------------------------------------------------------------------------------

- Net product revenue $200.5M (+16% YoY); GAAP net income $39.8M ($0.68 diluted EPS); non-GAAP adj. net income $53.8M ($0.92 diluted EPS).
- Reaffirms 2025 revenue guidance $820M-$860M; added 400 average patients to 7,600 in Q2.
- Phase 3 ZYN002 topline data in Fragile X syndrome on track for Q3 2025; targets ~80K U.S. patients.
- Entered research collaboration with CiRC Biosciences for refractory epilepsy & narcolepsy; $15M upfront paid.
- Settled ANDA litigation with Lupin; generic launch no earlier than Jan 2030 (or July 2030 with pediatric exclusivity).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1802665/000155837025010182/0001558370-25-010182-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1802665/000155837025010182/hrmy-20250805x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-010182

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer